CUREVAC V.
5CV.XETRA | Manufacture of pharmaceuticals, medicinal chemical and botanical products
CureVac V is a biopharmaceutical company focused on developing a new class of drugs based on messenger RNA (mRNA). The company's proprietary technology enables it to design and optimize mRNA constructs for various therapeutic applications, including prophylactic vaccines, cancer immunotherapies, and...Show More
Better Health for All
0
CureVac's core business is developing mRNA-based vaccines and therapies for a wide range of diseases, including cancer, infectious diseases, and genetic disorders, demonstrating a strong commitment to health improvement.
1
Its COVID-19 vaccine candidate, CVnCoV, showed 48-53% efficacy against symptomatic COVID-19 and 100% protection against hospitalization/death in the 18-60 age group.
2
The company has no revenue from products with negative health outcomes. Clinical trials for multiple candidates report favorable safety profiles; for CVnCoV, 8 serious adverse events in 5 recipients were considered vaccination-related, with no fatal serious adverse events.
3
CureVac commits to making Gates Foundation-funded products available at an affordable price in low and lower-middle-income countries and has a global access commitment agreement.
4
The company focuses on developing therapies for vulnerable populations, including cancer patients, newborns, children, the elderly, and those in developing countries.
5
CureVac has raised €1.94 billion in gross proceeds from equity financings since 2000, with 2024 capital expenditures of €14.9 million primarily for R&D.
6
The company's workforce increased from 440 in 2019 to 1,088 over 2024, including 245 employees with advanced scientific degrees.
7
CureVac develops prophylactic vaccines against infectious diseases, including UTIs, SARS-CoV-2, and influenza.
8
The company's Code of Conduct outlines a commitment to ethical conduct in clinical trials, including protecting participant safety and well-being.
9
However, CureVac's COVID-19 vaccine efforts did not come to fruition during the pandemic, and it terminated its Pandemic Preparedness Agreement with Germany in 2024.
10
The company is involved in multiple patent disputes, with some patents invalidated, and has granted a non-exclusive license for mRNA-based COVID-19 and/or influenza products to BioNTech and Pfizer as part of a settlement.
11
Fair Money & Economic Opportunity
0
No evidence available to assess CUREVAC V on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess CUREVAC V on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
30
CureVac's Supplier Code of Conduct, dated April 25, 2024, is contractually part of the relationship with all direct suppliers.
1
This code includes enforceable ethical-sourcing clauses covering human rights and environmental expectations, such as prohibitions on forced and child labor, non-discrimination, fair treatment, and compliance with applicable supply chain laws like the German Supply Chain Act.
2
Honest & Fair Business
0
No evidence available to assess CUREVAC V on Honest & Fair Business.
Kind to Animals
-20
CureVac's Supplier Code of Conduct, dated April 25, 2024, states that animal testing should be conducted using accepted and state-of-the-art methods, considering alternatives.
1
The company's Code of Conduct from September 2024 mentions compliance with animal welfare standards in research and development.
2
The 2024 Supplier Code of Conduct also outlines a commitment to humane treatment, minimizing animal testing, and using alternatives where scientifically proven and acceptable.
3
No War, No Weapons
0
No evidence available to assess CUREVAC V on No War, No Weapons.
Planet-Friendly Business
0
The provided articles, primarily annual report summaries and policy statements, focus on CureVac's financial performance, patent portfolio, and general commitments to ethical conduct, human rights, and supply chain due diligence. However, they consistently lack specific, quantitative data regarding environmental performance metrics. There is no information on greenhouse gas emissions (Scope 1, 2, or 3), renewable energy usage, water consumption, waste diversion rates, green building certifications, or alignment with the EU Sustainable Taxonomy.
1
Similarly, there is no data on climate-related targets (such as SBTi), carbon offsets, climate-positive investments, or climate risk disclosures (like TCFD alignment or scenario analysis).
2
The articles also do not provide details on biodiversity efforts, deforestation policies, or environmental compliance violations.
3
Therefore, no KPIs related to Planet-Friendly Business can be scored based on the evidence provided.
Respect for Cultures & Communities
0
No evidence available to assess CUREVAC V on Respect for Cultures & Communities.
Safe & Smart Tech
-30
CureVac's Code of Conduct states that it collects only necessary data and limits retention, which aligns with good data minimization practices.
1
The company is subject to various data privacy and protection laws, including HIPAA and GDPR, and mentions compliance efforts.
2
However, the 2023 Annual Report notes a material weakness in internal controls over financial reporting, which could indicate broader compliance gaps.
3
For user data control, applicants can update, add, and delete data in their account and delete their account and associated applications on the careers portal.
4
CureVac conducts regular internal vulnerability analyses and external penetration testing, and requires employee participation in a cybersecurity awareness program including phishing simulations.
5
Zero Waste & Sustainable Products
0
No specific, concrete data points were found across the provided articles to assess CureVac V against any of the 'Zero Waste & Sustainable Products' KPIs.
1
The articles primarily focus on financial reporting, legal disputes, and general risk disclosures, without detailing waste management performance, product design for circularity, or specific sustainability initiatives.
2